These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 24286312

  • 1. Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells.
    Shi X, Liu J, Ren L, Mao N, Tan F, Ding N, Yang J, Li M.
    BMB Rep; 2014 Apr; 47(4):221-6. PubMed ID: 24286312
    [Abstract] [Full Text] [Related]

  • 2. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, Pan S, Jiang H, Liu L.
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [Abstract] [Full Text] [Related]

  • 3. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L.
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [Abstract] [Full Text] [Related]

  • 4. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
    Zheng T, Yin D, Lu Z, Wang J, Li Y, Chen X, Liang Y, Song X, Qi S, Sun B, Xie C, Meng X, Pan S, Liu J, Jiang H, Liu L.
    Mol Cancer; 2014 May 31; 13():133. PubMed ID: 24884809
    [Abstract] [Full Text] [Related]

  • 5. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, Hosoi H.
    Clin Cancer Res; 2009 Jun 15; 15(12):4077-84. PubMed ID: 19509161
    [Abstract] [Full Text] [Related]

  • 6. Nutlin-3 Promotes TRAIL-Induced Liver Cancer Cells Apoptosis by Activating p53 to Inhibit bcl-2 and Surviving Expression.
    Zhang C, Ni J, Fan W, Hou J.
    Ann Clin Lab Sci; 2022 Jul 15; 52(4):601-610. PubMed ID: 36197780
    [Abstract] [Full Text] [Related]

  • 7. Much ado about Nutlin.
    Teoh NC.
    J Gastroenterol Hepatol; 2011 Feb 15; 26(2):213-5. PubMed ID: 21261708
    [No Abstract] [Full Text] [Related]

  • 8. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.
    Cell Death Dis; 2011 Apr 21; 2(4):e148. PubMed ID: 21509038
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK.
    PLoS One; 2015 Apr 21; 10(8):e0135101. PubMed ID: 26248031
    [Abstract] [Full Text] [Related]

  • 11. Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activation.
    Shi XL, Yang J, Mao N, Wu JH, Ren LF, Yang Y, Yin XL, Wei L, Li MY, Wang BN.
    Acta Pharmacol Sin; 2015 Feb 21; 36(2):252-8. PubMed ID: 25544361
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.
    Neuro Oncol; 2012 Jul 21; 14(7):859-69. PubMed ID: 22591662
    [Abstract] [Full Text] [Related]

  • 13. Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
    Wu Q, Wang X, Liu J, Zheng J, Liu Y, Li Y, Su F, Ou W, Wang R.
    Oncol Rep; 2016 Sep 21; 36(3):1325-32. PubMed ID: 27430152
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN, Jiang H, Chang H.
    Cancer Biol Ther; 2010 Sep 15; 10(6):567-78. PubMed ID: 20595817
    [Abstract] [Full Text] [Related]

  • 15. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T, Guo J, Song H, Zhu H, Di X, Min H, Wang Y, Chen G, Dai W, Ma J, Sun X, Ma J.
    Pathol Oncol Res; 2018 Jan 15; 24(1):75-81. PubMed ID: 28341911
    [Abstract] [Full Text] [Related]

  • 16. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P.
    Clin Cancer Res; 2011 Feb 15; 17(4):762-70. PubMed ID: 21106726
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, Looijenga L.
    Eur Urol; 2010 Apr 15; 57(4):679-87. PubMed ID: 19560254
    [Abstract] [Full Text] [Related]

  • 18. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G.
    Curr Drug Metab; 2007 May 15; 8(4):395-403. PubMed ID: 17504227
    [Abstract] [Full Text] [Related]

  • 19. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T, Yamada S, Ichwan SJ, Iseki S, Ohtani K, Otsu M, Ikeda MA.
    Biochem Biophys Res Commun; 2012 Jan 20; 417(3):931-7. PubMed ID: 22166212
    [Abstract] [Full Text] [Related]

  • 20. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S.
    Leukemia; 2009 Nov 20; 23(11):2090-101. PubMed ID: 19710698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.